The State University of New York

Other

Kyto Biopharma, Inc.

Edward V Quadros

Jeffrey M Sequeira

Sheldon P Rothenberg

A Charles Morgan, Jr

Maria Da Costa

The present invention provides anti-TCblR antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer, tumors and other proliferative diseases and disorders.

Antibodies to the B12-transcobalamin receptor

The present invention provides the amino acid and polynucleotide sequences of the transcobalamin receptor, as well as modulators of the transcobalamin receptor. Accordingly, the present invention provides compositions and methods for the treatment and prevention of diseases and disorders associated with cobalamin deficiency, including compositions and methods that promote cobalamin uptake. In addition, the present invention provides compositions and methods for the detection, treatment, and prevention of diseases associated with deregulated cell growth, including, e.g., cancer and autoimmune disorders, including compositions and methods that inhibit cobalamin uptake.

Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency

The present invention identifies autoantibodies to folate receptors. Methods to identify these autoantibodies to the human folate receptors are also provided. The present invention also contemplates diagnostic methods and test kits to be used in a clinical setting for identifying a subject at risk of folate-sensitive abnormalities or disorders as observed in neural tube defect complicated pregnancies. In addition, infertility, spontaneous abortion, male sterility, unsuccessful in vitro fertilization, neurologic disorders and impaired folate absorption may also be associated with these autoantibodies to folate receptors.

Method for detecting the affinity of folate receptor auto antibodies

There is disclosed anti-receptor and growth blocking agents to the vitamin B/transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the vitamin B/transcobalamin II receptor or binding sites, causing cellular depletion of vitamin B, thus inhibiting cell division or causing apoptosis. Anti-receptor and growth blocking agents of the present invention include proteins (such as antibodies and antibody derivatives), peptides and small organic molecules. In a preferred embodiment, the anti-receptor agent is an antibody to the vitamin B/transcobalamin II receptor.

Growing community of inventors

Brooklyn, NY, United States of America

Edward V Quadros